Document:

<PAGE>

                                                                   Exhibit 10.24
                                                                   -------------

                               AMENDMENT NO. 2 _
                               ---------------
                                      _TO

                            KIRIN-AMGEN, INC./AMGEN
                            -----------------------
                     G-CSF UNITED STATES LICENSE AGREEMENT
                     -------------------------------------

          THIS AMENDMENT N0. 2 ("Amendment No: 2") TO THAT CERTAIN KIRIN-AMGEN,
INC./AMGEN G-CSF UNITED STATES LICENCE AGREEMENT ("License Agreement"), is made
and entered into this 17th day of October, 1991 and is made effective as of the
                      ----
13th day of November, 1990, by and between AMGEN INC., a Delaware corporation
("Amgen"), and KIRIN-AMGEN, INC., a Delaware corporation ("Corporation").

                                R E C I T A L S

          A.   Amgen and Corporation have previously executed that certain
License Agreement regarding G-CSF.

          B.   The parties desire to incorporate certain changes into the
 License Agreement pursuant to this Amendment No. 2.

          NOW, THEREFORE, it is agreed as follows:

 1.       Article IV, Sections 4.01 and 4.03 at pages 7-8 of the License
 Agreement are hereby deleted and the following substituted in lieu thereof:

                                  "ARTICLE IV

                                    ROYALTY
                                    -------

          4.01 Royalty. Amgen shall-pay to the Company a royalty, at a rate of
               -------
          three percent (3%) of the Sales Value of G-CSF Products above $350
          million (U.S.), on G-CSF Products which are sold by Amgen, any of its
          Subsidiaries or sublicensees in the Territory pursuant to this
          Agreement.

          4.03 Payment of Royalties to Sloan-Kettering Cancer Center. Pursuant
               -----------------------------------------------------
          to that certain Agreement by and between Amgen and Sloan-Kettering
          Cancer Center ("S-K") dated February 12, 1986, certain royalties are
          to be paid to S-K with respect to sale of G-CSF products. The parties
          hereto confirm their prior agreement that the company shall bear and
          assume responsibility for the payments of royalties due S-K for sales
          of G-CSF Products in the United States above $350 million (U.S.) as
          renegotiated between Amgen and S-K. The royalty rate applicable to G-
          CSF Products above $350 million (U.S.) shall be three percent (3%) of
          the Sales Value of G-CSF Products."
<PAGE>

2.        Except to the extent as provided herein, the provisions of the License
Agreement, as amended, are hereby ratified and confirmed in all respects.

               IN WITNESS WHEREOF, the undersigned has caused this Amendment No.
2 to be executed as of the first day written above.

                                             AMGEN INC., a Delaware
                                             corporation

                                             By /s/ Gordon M. Binder
                                             Gordon M. Binder
                                             Chief Executive Officer

                                                                         "Amgen"

                                             KIRIN-AMGEN, INC., a
                                             Delaware corporation

                                             By /s/ T. Sasahara
                                             Toru Sasahara, Chairman

                                                                   "Corporation"<PAGE>

                                                                   Exhibit 10.25
                                                                   -------------

                               AMENDMENT NO. 10
                   TO SHAREHOLDERS' AGREEMENT OF KIRIN-AMGEN

     AMENDMENT NO. 10 (this "Amendment") made effective as of March 1, 1996 (the
"Effective Date") to the Shareholders' Agreement of Kirin-Amgen dated May 11,
1984 (as amended, the "Shareholders' Agreement") among Kirin Brewery Co., Ltd.,
a Japanese corporation with principal offices located at 10-1, Shinkawa 2-chome,
Chuo-ku, Tokyo, 104, Japan ("Kirin"), Amgen Inc. , a Delaware corporation with
principal offices located at Amgen Center, Thousand Oaks, California 91320
("Amgen") and Kirin-Amgen, Inc., a Delaware corporation with principal offices
located at c/o Amgen Europe AG, Grabenhof, 6010 Kirens, Switzerland ("Kirin-
Amgen").

                                   RECITALS

     WHEREAS, Amgen has discovered a novel growth factor that has erythropoiesis
stimulating activity ("NM321" as further defined in the NM321 Technology
Transfer Agreement effective as of March 1, 1996 among Kirin, Amgen, and Kirin-
Amgen, the "Technology Agreement").

     WHEREAS, Kirin and Amgen believe that NM321 may have important human
therapeutic uses and its discovery and development for future sale represents a
significant commercial opportunity.

     WHEREAS, Kirin-Amgen wishes to obtain rights to develop and commercialize
products based on NM321.

     WHEREAS, Kirin and Amgen now wish to add NM321 to their existing
relationship.

     NOW THEREFORE, in consideration of the mutual covenants expressed herein
and other good and valuable consideration, the parties agree as follows:

                                      -1-
<PAGE>

1.   NM321 RESEARCH AND DEVELOPMENT:
     ------------------------------

     1.01 Research and Development Project. Kirin and Amgen will commence the
          --------------------------------
joint development of NM321 as set forth in the Research, Development and
Technology Disclosure Agreement: NM321, effective as of March 1, 1996 among
Kirin, Amgen and Kirin-Amgen (the "Research Agreement"). Kirin and Amgen shall
each transfer and assign, perpetually and irrevocably, to Kirin-Amgen all right,
title and interest in and to all NM321 technology developed by such party in
connection with the Research and Development Project ("Research Project
Technology").

     1.02 Funding. Kirin-Amgen will fund all aspects of the joint development of
          -------
NM321 by Kirin and Amgen, except for the costs for human clinical testing of
NM321 outside of the U.S. and Japan, as set forth in the Research Agreement.

2.   ASSIGNMENTS. LICENSES AND CONSIDERATION.
     ---------------------------------------

     2.01 Assignments to Kirin-Amgen.
          --------------------------

           (a) Kirin. It is agreed that Kirin will transfer and assign to
               -----
     Kirin-Amgen, perpetually and irrevocably, all of its right, title and
     interest in and to the Kirin NM321 Technology (as defined in the Technology
     Agreement) and Kirin's interest in the Research Project Technology (as
     defined in the Technology Agreement), as of the Effective Date hereof. In
     consideration for such assignment, Kirin-Amgen will fund Kirin's future
     research and development activities as provided in the Research Agreement.

           (b) Amgen. It is agreed that Amgen will transfer and assign to
               -----
     Kirin-Amgen, perpetually and irrevocably, all of its right, title and
     interest in and to the Amgen NM321 Technology (as defined in the Technology
     Agreement) and Amgen's interest in the Research Project Technology (as
     defined in the Technology Agreement), as of the Effective Date hereof. In
     consideration for such assignment,

                                      -2-
<PAGE>

     Kirin-Amgen will fund Amgen's future research and development activities
     as provided in the Research Agreement.

     2.02 Consideration to Amgen. In consideration for the   assignment
          ----------------------
granted by Amgen to Kirin-Amgen to the Amgen NM321 Technology, Kirin-Amgen will
pay to Amgen one million U.S. dollars (US $1,000,000) within thirty (30) days of
the complete execution of this Amendment.

           2.03 Licenses to Kirin-Amgen.
                -----------------------

           (a) Kirin. It is agreed that Kirin will grant to Kirin-Amgen an
               -----
     exclusive worldwide royalty free license to the Kirin Core Technology (as
     defined in the Technology Agreement) in the Field of Activity (as defined
     in the Technology Agreement), as of the Effective Date hereof.

           (b) Amgen. It is agreed that Amgen will grant to Kirin-Amgen an
               -----
     exclusive worldwide royalty free license to the Amgen Core Technology (as
     defined in the Technology Agreement) in the Field of Activity (as defined
     in the Technology Agreement), as of the Effective Date hereof.

     2.04 Milestone Payments. In further consideration for Amgen's assignment of
          ------------------
Amgen NM321 Technology and Research Project Technology to Kirin-Amgen,
Kirin-Amgen will pay to Amgen progress payments upon the achievement of
specified milestones. The sum total for all of the progress payments will be
$19,000,000 plus an amount equal to Amgen's actual research and development
costs for the period from March 1, 1996 through December 31, 1996, which are
reimbursable pursuant to the Research Agreement, and shall be payable as set
forth in the Technology Agreement.

     2.05 Licenses to Kirin. It is agreed that Kirin-Amgen will grant to Kirin
          -----------------
an exclusive license to the NM321 Technology (as defined in the Technology
Agreement), Kirin Core Technology and Amgen Core Technology in the Kirin Core
Territory (as defined in the NM321 License Agreement effective as of March 1,
1996 between Kirin and Kirin-Amgen).

                                      -3-
<PAGE>

     2.06 Royalties from Kirin.
          --------------------

          (a) In exchange for the license to Kirin in the Kirin Core Territory,
     Kirin will pay to Kirin-Amgen a royalty equal to five percent (5%) of the
     Sales Value of NM321 Products (as defined in the Technology Agreement) sold
     by or on behalf of Kirin in the Kirin Core Territory.

          (b) In the event it is necessary for Kirin to pay a royalty to a
     third party for making, using, or selling an NM321 Product in a country in
     the Kirin Core Territory, the royalty Kirin pays to Kirin-Amgen in such
     country will be reduced by fifty percent (50%) of the third party royalty,
     provided, however, in no event will Kirin's royalties in any country be
     reduced to less than three percent (3%) by reason of third party royalty
     reduction.

          (c) In any case, Kirin's royalty obligation to Kirin-Amgen shall be
     reduced to two percent (2%) only with respect to the aggregate cumulative
     Sales Value of NM321 Products above Five Hundred Million US. Dollars (US
     $500,000,000).

     2.07 Licenses to Amgen. It is agreed that Kirin-Amgen will grant to Amgen
          -----------------
an exclusive license to the NM321 Technology, Kirin Core Technology and Amgen
Core Technology in the Amgen Core Territory, the Amgen Additional Territory, and
the Amgen Option Territory (as defined in the NM321 License Agreement effective
as of March 1, 1996 between Amgen and Kirin-Amgen; collectively, the "Amgen
Territory").

     2.08 Royalties from Amgen.
          --------------------

          (a) In exchange for the license to Amgen in the Amgen Core Territory,
     Amgen will pay to Kirin-Amgen a royalty equal to three percent (3%) of the
     Sales Value of NM321 Products sold by or on behalf of Amgen in the Amgen
     Core Territory. Amgen's royalty obligation to Kirin- Amgen in the Amgen
     Core Territory shall be reduced to two percent (2%) only with respect to
     the aggregate cumulative Sales Value of NM321 sold by or on behalf of Amgen
     in the Amgen Core Territory above five hundred million U.S. dollars (US
     $500,000,000).

                                      -4-
<PAGE>

           (b) In exchange for the license to Amgen in the Amgen Additional
     Territory, Amgen will pay to Kirin-Amgen a royalty equal to two percent
     (2%) of the Sales Value of NM321 Products sold by or on behalf of Amgen in
     the Amgen Additional Territory.

           (c) In exchange for the license to Amgen in the Amgen Option
     Territory, Amgen will pay to Kirin-Amgen a royalty equal to:

                 (i)   five percent (5%) of the Sales Value of NM321 Products
           sold by or on behalf of Amgen in countries in the Amgen Option
           Territory that are not signatories to the North American Free Trade
           Agreement (NAFTA); and

                 (ii)  two percent (2%) of the Sales Value of NM321 Products
           sold by or on behalf of Amgen in countries in the Amgen Option
           Territory that are signatories to the North American Free Trade
           Agreement (NAFTA).

           (d) In the event it is necessary for Amgen to pay a royalty to a
     third party for making, using, or selling an NM321 Product in any country
     in the Amgen Territory, the royalty Amgen pays to Kirin-Amgen in such
     country will be reduced by fifty percent (50%) of the third party royalty,
     provided, however, in no event will Amgen's royalties in any country be
     --------  -------
     reduced to less than two percent (2%) by reason of third party royalty
     reduction.

     2.09 Other Licenses.
          --------------

           (a) Kirin-Amgen Territory. Kirin-Amgen will retain the rights to the
               ---------------------
     NM321 Technology, Kirin Core Technology and Amgen Core Technology in the
     Kirin-Amgen Territory. Kirin-Amgen may license the rights to the NM321
     Technology, and sublicense the rights to Kirin Core Technology and Amgen
     Core Technology to Kirin, Amgen or a third party in such part or parts of
     the Kirin-Amgen Territory as Kirin-Amgen shall elect. Notwithstanding the
     foregoing, in no event will Kirin-Amgen sublicense the Kirin Core
     Technology or Amgen Core Technology to a third party without the consent of
     Kirin or Amgen, respectively. The goal of any license or sublicense by
     Kirin-Amgen of

                                      -5-
<PAGE>

the NM321 Technology, Amgen Core Technology and/or Kirin Core Technology in the
Kirin-Amgen Territory shall be the simultaneous worldwide utilization of the
NM321 Technology.

     (b) Kirin Core Territory and Amgen Territory. In the event either Kirin or
         ----------------------------------------
Amgen do not elect to commercialize NM321 Products in any country in their
respective territories, they will notify Kirin-Amgen in writing and upon such
notice the licenses to the NM321 Technology, and the sublicenses to Kirin Core
Technology and Amgen Core Technology granted by Kirin-Amgen to Kirin or Amgen,
as the case may be, in such country will terminate. Upon such termination, Kirin
with respect to countries in the Amgen Territory in which Amgen has not elected
to develop NM321 Products and Amgen with respect to countries in the Kirin Core
Territory in which Kirin has not elected to develop NM321 Products, will have
the option in their sole discretion on a country by country basis to elect to
develop NM321 Products in such country or countries upon such terms and
conditions as Kirin-Amgen shall determine. In the event Kirin or Amgen shall
not so elect, Kirin-Amgen may license the NM321 Technology, and sublicense Kirin
Core Technology and Amgen Core Technology to third parties in such country or
countries. Notwithstanding the foregoing, in no event will Kirin-Amgen
sublicense the Kirin Core Technology or Amgen Core Technology to a third party
without the consent of Kirin or Amgen, respectively.

3.   PATENTS.
     -------

     3.01 Filing, Prosecution and Maintenance.
          -----------------------------------

           (a) Amgen Core Territory. Amgen will file and prosecute the patent
               --------------------
     applications and applications for trademarks and copyright registration,
     and maintain resultant patents, trademarks and copyrights, included within
     the NM321 Technology in the Amgen Core Territory. The associated costs and
     expenses will be borne by Amgen.

           (b) Amgen Additional Territory and Amgen Option Territory. Kirin-
               -----------------------------------------------------
     Amgen will file and prosecute the patent applications and applications for
     trademarks and copyright registration, and maintain resultant patents,
     trademarks and copyrights, included

                                      -6-
<PAGE>

     within the NM321 Technology in the Amgen Additional Territory and Amgen
     Option Territory. The associated costs and expenses will be borne by Kirin-
     Amgen.

           (c) Kirin Core Territory. Kirin will file and prosecute the patent
               --------------------
     applications and applications for trademarks and copyright registration,
     and maintain resultant patents, trademarks and copyrights, included within
     the NM321 Technology in the Kirin Core Territory . The associated costs and
     expenses will be borne by Kirin.

           (d) Kirin-Amgen Territory. Kirin-Amgen will file and prosecute the
               ---------------------
     patent applications and applications for trademarks and copyright
     registration, and maintain resultant patents, trademarks and copyrights,
     included within the NM321 Technology in the Kirin-Amgen Territory. The
     associated costs and expenses will be borne by Kirin-Amgen.

           (e) Core Technology. Kirin will file and prosecute the patent
               ---------------
     applications and applications for trademarks and copyright registration,
     and maintain resultant patents, trademarks and copyrights, included within
     the Kirin Core Technology worldwide. Kirin shall bear all costs and
     expenses associated therewith. Amgen will file and prosecute the patent
     applications and applications for trademarks and copyright registration,
     and maintain resultant patents, trademarks and copyrights, included within
     the Amgen Core Technology worldwide. Amgen shall bear all costs and
     expenses associated therewith.

     3.02 Enforcement.
          -----------

           (a) Amgen Territory. Amgen will have the first right, but not the
               ---------------
     obligation, to enforce the technology included within NM321 Technology
     within the Amgen Territory, and payment of the associated costs and
     expenses will be borne as agreed between Amgen and Kirin-Amgen on a case by
     case basis.

           (b) Kirin Core Territory. Kirin will have the first right, but not
               --------------------
     the obligation, to enforce the technology included within NM321 Technology
     within the Kirin Core Territory, and payment of the

                                      -7-
<PAGE>

     associated costs and expenses will be borne as agreed between Kirin and
     Kirin-Amgen on a case by case basis.

           (c) Kirin-Amgen Territory. Kirin-Amgen will have the first right, but
               ---------------------
     not the obligation, to enforce the technology included within NM321
     Technology within the Kirin-Amgen Territory, and payment of the associated
     costs and expenses will be borne by Kirin-Amgen.

           (d) Core Technology. The responsibility for enforcement of the
               ---------------
     technology included within Kirin Core Technology worldwide will be borne by
     Kirin. Kirin shall bear all costs and expenses associated therewith. The
     responsibility for enforcement of the technology included within Amgen Core
     Technology worldwide will be borne by Amgen. Amgen shall bear all costs and
     expenses associated therewith.

     3.03 Defense of NM321 Patents. Kirin-Amgen will be responsible for and
          ------------------------
control the defenses of patents and patent applications included within the
NM321 Technology and bear all costs and expenses associated therewith, provided,
                                                                       --------
however, Amgen and Kirin each will be responsible for and control the defenses
-------
of patents and patent applications included within the NM321 Technology and bear
all costs and expenses associated therewith in Amgen Core Territory and Kirin
Core Territory, respectively. As used in this Section 3.03, "defenses" shall
include without limitation those involved in oppositions, interferences,
revocation actions, and nullity actions.

     3.04 Defense in Actions Based on Third Party Patent Infringement.
          -----------------------------------------------------------

           (a) Amgen Territory. Amgen will defend any suit or action claiming
               ---------------
     infringement of any third party patent right through the making, having
     made, using, selling or having sold NM321 Products in the Amgen Territory.
     Kirin-Amgen shall bear all costs and expenses associated therewith.

           (b) Kirin Core Territory. Kirin will defend any suit or action
               --------------------
     claiming infringement of any third party patent right through the

                                      -8-
<PAGE>

     making, having made, using, selling or having sold NM321 Products in the
     Kirin Core Territory. Kirin-Amgen shall bear all costs and expenses
     associated therewith.

           (c) Kirin-Amgen Territory. Kirin-Amgen will defend any suit or action
               ---------------------
     claiming infringement of any third party patent right through the making,
     having made, using, selling or having sold NM321 Products in the Kirin-
     Amgen Territory. Kirin-Amgen shall bear all costs and expenses associated
     therewith.

4.   CONSISTENCY WITH SHAREHOLDERS' AGREEMENT; RATIFICATION.
     ------------------------------------------------------

     4.01 Consistency. The rights and obligations of the parties with respect to
          -----------
this Amendment No. 10 as an expansion of Kirin-Amgen's business opportunities
are otherwise consistent with the Shareholders' Agreement.

     4.02 Ratification. All of the terms and conditions of the Shareholders'
          ------------
Agreement as amended by this Amendment No. 10 are hereby ratified and confirmed
in all respects.

5.   FURTHER INSTRUMENTS
     -------------------

     5.01 Further Instruments. Each party hereto agrees to perform any and all
          -------------------
further acts and execute and deliver any and all further instruments which may
be reasonable or necessary to carry out the provisions of this Amendment No. 10
and to carry out this further business purpose of Kirin-Amgen.

                                      -9-
<PAGE>

     IN WITNESS WHEREOF, the undersigned have caused this Amendment to be
executed by their duly authorized representatives in the manner legally binding
upon them.

                                    Kirin Brewery Co., Ltd.

                                    By: /s/ Koichiro Aramaki
                                    Koichiro Aramaki Ph.D.
                                    Title: President, Pharmaceutical Div.

                                       November 28, 1996
                                    Date

                                    Amgen Inc.

                                    By: /s/ K. Sharer
                                           Kevin Sharer
                                    Title:

                                          December 9, 1996
                                    Date

                                    Kirin-Amgen, Inc.

                                    By: /s/ Daryl Hill
                                             Daryl Hill
                                    Title:

                                           December 9, 1996
                                    Date

                                     -10-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]